Key Highlights
- First-quarter adjusted EPS of $0.32 exceeded analyst projections of $0.26–$0.31
- Quarterly sales reached $3.91 billion, marking a 4.5% year-over-year increase and surpassing the $3.84 billion forecast
- The Skin Health and Beauty division delivered standout performance with 8.4% revenue growth
- Kimberly-Clark’s $40 billion purchase agreement remains on schedule for completion in H2 2026
- Forward outlook withheld in light of the upcoming transaction
Kenvue (KVUE) unveiled first-quarter earnings on Thursday that exceeded Wall Street projections on both the top and bottom lines, sending shares higher by approximately 1.78% during trading.
The consumer healthcare giant delivered adjusted earnings of $0.32 per share, surpassing analyst consensus estimates ranging from $0.26 to $0.31. Quarterly revenue totaled $3.91 billion for the period ending March 29, representing a 4.5% increase from the prior-year figure of $3.74 billion and exceeding Wall Street’s $3.84 billion projection.
Organic revenue advanced 0.7%, fueled by 1.0% positive pricing effects, though partially counterbalanced by a 0.3% decrease in volume.
KVUE shares had declined 0.11% during pre-market activity before the earnings announcement, but the strong performance helped restore investor confidence.
Chief Executive Kirk Perry highlighted that the organization achieved both net and organic revenue expansion for the second straight quarter, accompanied by year-over-year enhancements in gross margin, operating margin, and earnings per share.
Adjusted gross profit margin widened by 80 basis points to 60.8%, benefiting from supply chain efficiencies and positive pricing dynamics that mitigated inflationary pressures and tariff challenges. Adjusted operating income margin climbed to 24.0% compared to 19.8% in the corresponding period last year.
Skin Health and Beauty Division Drives Performance
The Skin Health and Beauty category emerged as the top contributor, recording net sales growth of 8.4% to reach $1.06 billion. Popular brands including Neutrogena and Aveeno fueled worldwide consumer demand.
The Self Care division posted 1.9% growth while Essential Health advanced 4.9%. Self Care performance was constrained by an unusually mild cold and flu season throughout key geographical markets.
Management indicated that its ongoing restructuring initiative is projected to generate approximately $250 million in pre-tax expenses throughout the current fiscal year.
Pending Kimberly-Clark Transaction Influences Forecast
Kenvue opted not to provide forward-looking guidance given the pending $40 billion acquisition agreement with Kimberly-Clark, which is anticipated to finalize during the second half of 2026, contingent upon international regulatory clearances.
Kimberly-Clark shares appreciated roughly 2.05% during the trading session, as the quarterly results were interpreted positively for the acquiring company.
RBC Capital Markets analyst Nik Modi characterized the performance as encouraging for Kimberly-Clark, stating “Kenvue’s fundamentals seem to be stabilizing.” He observed that immediate stock movement will probably be influenced more significantly by transaction timing and legal developments rather than core operational metrics.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
